Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | HTT | P42858 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956882 | 0.72 | GPR3 (0.37) | ADORA2AALDH1A1HTTLMNA | |
| SCHEMBL21295742 | 0.70 | NOTUM (0.40) | KDM4ERAB9ANPC1PDE5AALDH1A1 | |
| SCHEMBL14782179 | 0.70 | PDPK1 (0.46) | KDM4ERAB9ANPC1ADORA2AALDH1A1 | |
| SCHEMBL13518120 | 0.68 | MEN1 (0.36) | KDM4EL3MBTL1RAB9ANPC1ADORA2A | |
| SCHEMBL5877790 | 0.68 | GPR3 (0.33) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL2966653 | 0.67 | KDM4E (0.35) | KDM4EL3MBTL1ALDH1A1MAPTHPGD | |
| SCHEMBL29658035 | 0.66 | ACHE (0.56) | KDM4EL3MBTL1RAB9ANPC1ADORA2A | |
| SCHEMBL13130593 | 0.66 | ACHE (0.56) | KDM4EL3MBTL1RAB9ANPC1ADORA2A | |
| SCHEMBL29945128 | 0.66 | LTA4H (0.47) | KDM4EL3MBTL1RAB9ANPC1ADORA2A | |
| SCHEMBL9927346 | 0.66 | LTA4H (0.47) | KDM4EL3MBTL1RAB9ANPC1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | claimed |
| CN-101704810-A | Cycloalkyl inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO | 2010-05-12 | — | — | CN | claimed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | claimed |
| CN-1732146-A | Cycloalkyl inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | CN | claimed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | claimed |
| EP-1507504-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | claimed |
| WO-2003063797-A2 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | claimed |
| EP-0915837-A1 | GLYOXYLIC ACID DERIVATIVES | BAYER AG (DE) | 1999-05-19 | — | — | EP | claimed |
| WO-1998003474-A1 | GLYOXYLIC ACID DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-29 | — | — | WO | claimed |
| US-5457096-A | Antibiotic | AMERICAN CYANAMID COMPANY (US) | 1995-10-10 | — | — | US | claimed |
| CN-103534833-B | Organic Electroluminescent Multicolor Light-Emitting Device | 索尼株式会社 | 2016-07-20 | — | — | CN | disclosed |
| CN-105792823-A | Pharmaceutical composition for treating malignant tumor | 皮特尼制药股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| CN-1048240-C | Novel T-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 2000-01-12 | — | — | CN | disclosed |
| EP-0889726-A4 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| CN-1072172-A | Novel 7-replacement-9-substituted-amino-6-demethyl-6-deoxidation tsiklomitsin | AMERICAN CYANAMID CO (US) | 1993-05-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | KDM4E 820/4885L3MBTL1 1226/4885RAB9A 2415/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | KDM4E 820/4885L3MBTL1 1226/4885RAB9A 2415/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | KDM4E 1323/4885L3MBTL1 1424/4885RAB9A 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.